Eflornithine (hydrochloride hydrate)

Eflornithine hydrochloride hydrate (DFMO hydrochloride hydrate) is a specific, irreversible inhibitor of the enzyme ornithine decarboxylase. Eflornithine hydrochloride hydrate is a medication for the treatment of African trypanosomiasis and excessive facial hair growth in women[1].

Product Specifications

CAS Number

[96020-91-6]

Product Name Alternative

DFMO hydrochloride hydrate; MDL-71782 hydrochloride hydrate; RMI-71782 hydrochloride hydrate; α-difluoromethylornithine hydrochloride hydrate

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Parasite

Type

Reference compound

Related Pathways

Anti-infection

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Eflornithine-hydrochloride,-hydrate.html

Purity

99.90

Solubility

H2O : 83.33 mg/mL (ultrasonic)

Smiles

NC(CCCN)(C(F)F)C(O)=O.[H]Cl.O

Molecular Formula

C6H15ClF2N2O3

Molecular Weight

236.64

Precautions

H302, H315, H319, H335

References & Citations

[1]Burri C, et al. Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res. 2003 Jun;90 Supp 1:S49-52.|[2]Balfour JA, et al. Topical eflornithine. Am J Clin Dermatol. 2001;2 (3) :197-201; discussion 202.|[3]Kumar A, et al. A method to improve the efficacy of topical eflornithine hydrochloride cream. Drug Deliv. 2016 Jun;23 (5) :1495-501.|[4]Lipke DW, et al. Eflornithine alters changes in vascular responsiveness associated with coarctation hypertension. Clin Exp Hypertens. 1997 Apr;19 (3) :297-312.